Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

被引：30

作者：

Cheng, Hengmiao ^{[1
]}

Orr, Suvi T. M. ^{[1
]}

Bailey, Simon ^{[1
]}

Brooun, Alexei ^{[1
]}

Chen, Ping ^{[1
]}

Deal, Judith G. ^{[1
]}

Deng, Yali L. ^{[1
]}

Edwards, Martin P. ^{[1
]}

Gallego, Gary M. ^{[1
]}

Grodsky, Neil ^{[1
]}

Huang, Buwen ^{[1
]}

Jalaie, Mehran ^{[1
]}

Kaiser, Stephen ^{[1
]}

Kania, Robert S. ^{[1
]}

Kephart, Susan E. ^{[1
]}

Lafontaine, Jennifer ^{[1
]}

Ornelas, Martha A. ^{[1
]}

Pairish, Mason ^{[1
]}

Planken, Simon ^{[1
]}

Shen, Hong ^{[1
]}

Sutton, Scott ^{[1
]}

Zehnder, Luke ^{[1
]}

Almaden, Chau D. ^{[1
]}

Bagrodia, Shubha ^{[1
]}

Falk, Matthew D. ^{[1
]}

Gukasyan, Hovhannes J. ^{[1
]}

Ho, Caroline ^{[1
]}

Kang, Xiaolin ^{[1
]}

Kosa, Rachel E. ^{[1
]}

Liu, Ling ^{[1
]}

Spilker, Mary E. ^{[1
]}

Timofeevski, Sergei ^{[1
]}

Visswanathan, Ravi ^{[1
]}

Wang, Zhenxiong ^{[1
]}

Meng, Fanxiu ^{[2
]}

Ren, Shijian ^{[2
]}

Shao, Li ^{[2
]}

Xu, Feng ^{[2
]}

Kath, John C. ^{[1
]}

机构：

[1] Pfizer Worldwide Res & Dev, La Jolla Labs, San Diego, CA 92121 USA

[2] Wuxi AppTec, Shanghai 200131, Peoples R China

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 64卷 / 01期

关键词：

I PI3K INHIBITOR; PHASE-I; POTENT; DISCOVERY; PF-04691502; NVP-BYL719; PATHWAY;

D O I：

10.1021/acs.jmedchem.0c01652

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3K alpha is one of the most frequently mutated kinases in human cancer. A PI3K alpha-selective inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a PI3K alpha-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds, exemplified by 2,2-difluoroethyl (3S)-3-{[2'-amino-5-fluoro-2-(morpholin-4-yl)-4,5'-bipyrimidin-6-yl] amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (1) (PF-06843195), with high PI3K alpha potency and unique PI3K isoform and mTOR selectivity were discovered. We describe here the details of the design and synthesis program that lead to the discovery of 1.

引用

页码：644 / 661

页数：18

共 34 条

[1]

Braun M.G., 2017, DISCOVERY GDC 0077 H, pMEDI

[2] Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer [J].

Burger, Matthew T. ;

Pecchi, Sabina ;

Wagman, Allan ;

Ni, Zhi-Jie ;

Knapp, Mark ;

Hendrickson, Thomas ;

Atallah, Gordana ;

Pfister, Keith ;

Zhang, Yanchen ;

Bartulis, Sarah ;

Frazier, Kelly ;

Ng, Simon ;

Smith, Aaron ;

Verhagen, Joelle ;

Haznedar, Joshua ;

Huh, Kay ;

Iwanowicz, Ed ;

Xin, Xiaohua ;

Menezes, Daniel ;

Merritt, Hanne ;

Lee, Isabelle ;

Wiesmann, Marion ;

Kaufman, Susan ;

Crawford, Kenneth ;

Chin, Michael ;

Bussiere, Dirksen ;

Shoemaker, Kevin ;

Zaror, Isabel ;

Maira, Sauveur-Michel ;

Voliva, Charles F. .

ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10) :774-779

[3] Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors [J].

Burger, Matthew T. ;

Knapp, Mark ;

Wagman, Allan ;

Ni, Zhi-Jie ;

Hendrickson, Thomas ;

Atallah, Gordana ;

Zhang, Yanchen ;

Frazier, Kelly ;

Verhagen, Joelle ;

Pfister, Keith ;

Ng, Simon ;

Smith, Aaron ;

Bartulis, Sarah ;

Merrit, Hanne ;

Weismann, Marion ;

Xin, Xiaohua ;

Haznedar, Joshua ;

Voliva, Charles F. ;

Iwanowicz, Ed ;

Pecchi, Sabina .

ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (01) :34-38

[4]

Chen P., 2015, Patent No. [WO2015155624A1, 2015155624]

[5]

Chen P., 2017, Patent No. [WO2017009751A12017, 2017009751]

[6] Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design [J].

Chen, Ping ;

Deng, Ya-Li ;

Bergqvist, Simon ;

Falk, Matthew D. ;

Liu, Wei ;

Timofeevski, Sergei ;

Brooun, Alexei .

PROTEIN SCIENCE, 2014, 23 (10) :1332-1340

[7] Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series [J].

Cheng, Hengmiao ;

Hoffman, Jacqui E. ;

Le, Phuong T. ;

Pairish, Mason ;

Kania, Robert ;

Farrell, William ;

Bagrodia, Shubha ;

Yuan, Jing ;

Sun, Shaoxian ;

Zhang, Eric ;

Xiang, Cathy ;

Dalvie, Deepak ;

Rahavendran, Sadayappan V. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) :2787-2792

[8] Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design [J].

Cheng, Hengmiao ;

Li, Chunze ;

Bailey, Simon ;

Baxi, Sangita M. ;

Goulet, Lance ;

Guo, Lisa ;

Hoffman, Jacqui ;

Jiang, Ying ;

Johnson, Theodore Otto ;

Johnson, Ted W. ;

Knighton, Daniel R. ;

Li, John ;

Liu, Kevin K. -C. ;

Liu, Zhengyu ;

Marx, Matthew A. ;

Walls, Marlena ;

Wells, Peter A. ;

Yin, Min-Jean ;

Zhu, Jinjiang ;

Zientek, Michael .

ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (01) :91-97

[9] Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design [J].

Cheng, Hengmiao ;

Bagrodia, Shubha ;

Bailey, Simon ;

Edwards, Martin ;

Hoffman, Jacqui ;

Hu, Qiyue ;

Kania, Robert ;

Knighton, Daniel R. ;

Marx, Matthew A. ;

Ninkovic, Sacha ;

Sun, Shaoxian ;

Zhang, Eric .

MEDCHEMCOMM, 2010, 1 (02) :139-144

[10] Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate [J].

Coburn, SP ;

Mahuren, JD ;

Jain, M ;

Zubovic, Y ;

Wortsman, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3951-3957

← 1 2 3 4 →